Axon Neuroscience SE is a clinical-stage biotechnology company focused on the development of peptide-based vaccines and therapies against Alzheimer's disease and other tau-related neurodegenerative disorders. Their lead candidate, AADvac1, is an active vaccine designed to target pathological tau proteins, which are a hallmark of Alzheimer's disease. The company's mission is to bring effective treatments and diagnostic tools to patients suffering from these devastating conditions, leveraging deep expertise in immunology and neuroscience.
The headquarters serves as the central hub for research and development, clinical trial management, corporate strategy, and administrative operations.
While specific architectural details are not widely publicized, the facility likely includes advanced laboratory spaces for biochemical and immunological research, as well as office areas for its scientific, clinical, and administrative teams.
The work culture at Axon Neuroscience SE is likely research-intensive, collaborative, and mission-driven, with a strong focus on scientific innovation and addressing the urgent unmet medical needs in neurodegenerative diseases. Employees are typically highly skilled scientists, clinicians, and professionals dedicated to drug discovery and development.
The Bratislava headquarters is significant as it anchors Axon's R&D activities in Central Europe, allowing it to draw on regional scientific talent and collaborate with European research institutions and clinical sites for its trials.
While Axon Neuroscience SE's primary operations are based in Bratislava, Slovakia, its clinical trials and research collaborations often extend internationally. The company has engaged with clinical trial sites across various European countries to ensure diverse patient recruitment for its studies on Alzheimer's disease. Its scientific contributions and potential therapeutic impact are global in scope, addressing a worldwide health challenge.
Dvorakovo nabrezie 10
Bratislava
Bratislava Region
Slovakia
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AXON Neuroscience' leadership includes:
AXON Neuroscience has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major widely reported executive hires or exits at Axon Neuroscience SE in the last 12-18 months. The leadership team appears relatively stable as of late 2023/early 2024. Roman Koci joined as COO and Matej Ondrus as CFO in 2022, which is slightly outside the 12-month window but represents recent significant additions.
Discover the tools AXON Neuroscience uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Axon Neuroscience SE likely uses common corporate email formats. Based on observed patterns in the industry and executive communications, the most probable formats are [first_initial][last]@[domain] or [first].[last]@[domain].
[first_initial][last]@axon-neuroscience.com or [first].[last]@axon-neuroscience.com
Format
mfresser@axon-neuroscience.com
Example
80%
Success rate
PR Newswire • 2023-03-07
Axon Neuroscience announced the publication of positive results from its Phase I study of AADcovI, a peptide-based vaccine candidate against COVID-19. The study, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, demonstrated that AADcovI was safe, well-tolerated, and induced a robust neutralizing antibody response in elderly participants....more
Axon Neuroscience Website (Press Release) • 2022-10-27
Axon Neuroscience SE announced the appointment of Roman Koci, PhD, MBA, as its new Chief Operating Officer (COO). This strategic move aims to strengthen the company's operational capabilities as it advances its pipeline of treatments for neurodegenerative diseases....more
Alzheimer's Research UK • 2021-07-29
Axon Neuroscience reported encouraging long-term results from their phase II clinical trial, ADAMANT, for their Alzheimer's vaccine AADvac1. The vaccine, which targets the tau protein, showed a good safety profile and induced a robust immune response. Exploratory analysis suggested potential benefits on cognitive decline and reduction in certain disease biomarkers....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AXON Neuroscience, are just a search away.